Tomorrow Unveiled: Your Weekly Tech Briefing
Eli Lilly just entered the longevity race with retatrutide - a triple-receptor drug showing 28% weight loss and cellular aging reversal. We break down how 13 billion dollars in GLP-1 revenue is funding the future of anti-aging medicine, AI drug discovery, and why Big Pharma's institutional validation marks the professionalization of longevity science. This is the moment pharmaceutical scale meets lifespan extension. #GLP1 #Longevity #Retatrutide #EliLilly #AntiAging #Biotech #DrugDiscovery #HealthSpan Watch on YouTube: https://www.youtube.com/watch?v=qaN42HaEWzw
254 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Tomorrow Unveiled: Your Weekly Tech Briefing!